1 / 62

بسم الله الرحمن الرحيم

بسم الله الرحمن الرحيم. علایم بالینی و درمان هیپوتیروییدی مادرزادی. ارایه دهنده: دکتر مجید ولی زاده. References:. Up to date 2009 (17.3). Thyroid Embryology. Derived from endodermal tissue at base of tongue Embryonal remnants form Thyroglossal duct; pyramidal lobe; lingual thyroid

ryann
Download Presentation

بسم الله الرحمن الرحيم

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. بسم الله الرحمن الرحيم

  2. علایم بالینی و درمان هیپوتیروییدی مادرزادی ارایه دهنده: دکتر مجید ولی زاده

  3. References: • Up to date 2009 (17.3) • .

  4. Thyroid Embryology • Derived from endodermal tissue at base of tongue • Embryonal remnants form Thyroglossal duct; pyramidal lobe; lingual thyroid • Fuse with C-cells (neural crest origin), derived from the the 5th branchial arch • C-cells scattered through posterior/superior lobes

  5. Major causes of congenital hypothyroidism, approximate frequency • Thyroid dysgenesis - ectopia, aplasia, or hypoplasia (1:4500) • Inborn errors of thyroxine synthesis (dyshormonogeneses) (1:30,000) • Maternal antibody-mediated hypothyroidism (1:25,000-1:100,000) • Central hypothyroidism (1:25,000-1:100,000) • Transient hypothyroidism (1:100 Europe)

  6. Lingual thyroid

  7. CLINICAL MANIFESTATIONS • More than 95 percent asymptomatic • umbilical cord serum T4 concentrations are about 25 to 50 % • inadequate, functioning thyroid tissue

  8. Figure 15-7. Brain neurologic development relative to thyroid function in the rat and human. TH, thyroid hormones; dpc, days postconception; dpn, days postnatal. (From Porterfield and Hendrich, with permission.)

  9. Clinical manifestations: • Birth length and weight • head circumference • other congenital anomalies ↑

  10. Lethargy slow movement hoarse cry feeding problems constipation macroglossia umbilical hernia large fontanels hypotonia dry skin hypothermia prolonged jaundice A few with thyroid dyshormonogenesis : a palpable goiter CLINICAL MANIFESTATIONS

  11. Figure 15-12. Ten year old female with severe 1° hypothyroidism due to primary myxedema before (A) and after (B) treatment. Presenting complaint was poor growth. Note the dull facies, relative obesity and immature body proportions prior to treatment. At age 10 years she had not lost a single deciduous tooth. After treatment was initiated (indicated by the arrow in Panel C), she lost 6 teeth in 10 months and had striking catch up growth. Bone age was 5 years at a chronologic age of 10 years. TSH receptor blocking antibodies were negative. 

  12. Treatment:

  13. Figure 15-4. Postnatal TSH, T4, T3, and rT3 secretion in the full-term and premature infant in the first week of life (modified from Fisher DA: Disorders of the thyroid in the newborn and infant. In: Sperling M (ed) Pediatric Endocrinology, WB Saunders Co., Philadelphia, 51, 1996).

  14. Low T4 and Elevated TSH Values • Low T4 + TSH > 40 :is considered to have primary hypothyroidism (Iran: TSH> 5 ) • examination (immediately ) + confirmatory serum testing to verify the diagnosis. • screening TSH concentration is only slightly elevated but < 40 mU/L, another filter-paper specimen should be obtained for a second newborn screening.

  15. Low T4 + high TSH • 10% Hypothyroids ( TSH : 20-40) • It is important that age appropriate normative values be used. • Range for TSH for the most common time of TSH re-evaluation (between 2 and 6 weeks of age) is 1.7to9.1mU/L.

  16. Normal T4 and Elevated TSH Values ( Hyperthyrotropinemia) • Etiology : 1) transient or permanent thyroid abnormality 2) delayed maturation of the hypothalamic-pituitary axis. 3) Inactivation mutations in the TSH-R cause compensated, mild (subclinical) primary hypothyroidism in the neonatal period.

  17. There is controversy regarding the need for TH therapy in this setting.

  18. High TSH + normal T4 • Most physicians would consider a persistent basal TSH concentration higher than 10 mU/L (after the first 2 weeks of age) to be abnormal. • If such infants are not treated, measurement of FT4 and TSH should be repeated in 2 and 4 weeks, and treatment should be initiated promptly if the FT4 and TSH concentrations have not normalized.

  19. High normal TSH • The management of infants with TSH elevations between 6 and 10 mU/L that persist after the first month of life is even more controversial. • A TSH range of 1.7 to 9.1 mU/L has been reported for children 2 to 20 weeks of age • if a decision is made to treat such children , a trial off therapy at 3 years of age should be performed.

  20. Low T4 and Normal TSH Values • 2 SDs below the mean for the reference range for age , usually < 10 µg/dL in the newborn infant 1) Hypothalamic immaturity 2) during illness 3) protein-binding disturbances such as TBG deficiency(1 in 5000) 4) central hypothyroidism (l in 25 000 to l in 50 000 newborn infants) 5) primary hypothyroidism and delayed TSH elevation (l in 100 000 newborn infants). • Transient hypothyroxinemia is seen to some extent in many preterm infants

  21. Figure 15-4. Postnatal TSH, T4, T3, and rT3 secretion in the full-term and premature infant in the first week of life (modified from Fisher DA: Disorders of the thyroid in the newborn and infant. In: Sperling M (ed) Pediatric Endocrinology, WB Saunders Co., Philadelphia, 51, 1996).

  22. Hypothyroxinemia • Take no further action, to follow-up with serial filter-paper screening tests until the T4 value becomes normal, or to request second blood sample for measurement of FT4 and TSH concentration. • Most infants with low T4 and normal TSH have normal FT4 values, and subsequent thyroid function test results are normal

  23. Transient TSH Elevation • Intrauterine exposure to maternal anti thyroid drugs, maternal TRBAbs • Heterozygous thyroid oxidase 2 deficiency • Germ-line mutations in the TSH-R, endemic • Iodine deficiency • Prenatal or postnatal exposure to excess iodides ( povidone iodine, iodinated contrast materials)

  24. CLINICAL MANAGEMENT OF NEWBORN INFANTS WITH LOW T4 AND ELEVATED TSH VALUES • Infants with low T4 and elevated TSH concentrations have CH until proven otherwise. 1) Consultation with a endocrinologist is recommended to facilitate diagnostic evaluation and optimal management.

  25. Clinical management... 2) A complete history, including prenatal thyroid status (maternal drugs and medications) and family history should be obtained, and physical examination should be performed. 3) Serum should be obtained for confirmatory measurements of TSH and FT4.

  26. Clinical management... 4) Education of parents by trained personnel using booklets or visual aids is highly desirable. 5) Optional diagnostic studies include - -thyroid ultrasonography -iodine 123 (123I) - sodium technetium 99m pertechnetate (99mTc) thyroid uptake -and/or scan to identify functional thyroid tissue.

  27. Treatment • Treatment Should Begin As Soon As Possible, Preferably Within The First Two Weeks of Life

  28. Treatment The Goal Of Treatment To Ensure Normal Growth &Development • T4 10 To 16 µg/dl • TSH Around 1 mIu/L

  29. Treatment : • The goal of therapy is to normalizeT4 within 2 weeksand TSH within 1 month. • An initial dosage of 10 to 15 g/kg of L-T4 (depending on the severity of the initial hypothyroidism) • Administration of L-T4 is the treatment of choice.

  30. Treatment : • The pill should be crushed and suspended in a few milliliters of formula, breast milk, or water. • Only T4 tablets should be used • T4 is expected to increase to more than 10 µg/dL • FT4 is expected to increase to more than 2 ng/dL by 2weeks after initiating therapy • TSH should normalize by 1 month.

  31. Treatment : • The L-T4 dose should be adjusted according to the infant’s clinical response and serum FT4 and TSH concentrations. • During therapy, the serum total T4 or FT4 should and might be in the upper half of the reference range (target values depend on the assay method used [T4: 10–16 g/dL (130–206 nmol/L); FT4: 1.4 –2.3 ng/dL (18–30 pmol/L)]) during the first 3 years of life with a low normal serum TSH. • The latter may sometimes be delayed because of relative pituitary resistance.

  32. Between 1 and 5 days of life, the normal range for serum total T4 concentrations is about 10 to 22 µg/dL • Between 1 and 4 weeks of life, the normal range for serum total T4 concentrations is 7 to 16 µg/dL

  33. Delay in normalization of TSH: • Normal or increased serum (→ or↑ ) T4 and an inappropriately high TSH concentration, the T4 value is used to titrate the dose. • Nonadherence to the treatment is the most common cause of persistent TSH elevation and should be excluded.

  34. Target of treatment: • TSH levels should be maintained between 0.5 and 2.0 mU/L during the first 3 years of life • During TH therapy, 4 or more episodes of insufficiently suppressed TSH (5 mU/L) after the age of 6 months were the most important variables associated with school delay

  35. DIAGNOSTIC STUDIES • venipuncture to confirm • If the diagnosis of hypothyroidism is confirmed • thyroid radionuclide uptake and imaging • Ultrasonography • serum thyroglobulin assay • thyroid autoantibodies • urinary iodine excretion • These tests usually do not alter treatment

  36. Recommended follow-up • At 2 and 4 weeks after the initiation of T4 treatment • Every 1 to 2 months during the first year of life • Every 2 to 3 months between 1 and 3 years of age • Every 3 to 12 months thereafter until growth is complete • Two weeks after any change in dosage

More Related